search
Back to results

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Azilsartan tablets
Azilsartan placebo tablets
Olmesartan medoxomil tablets
olmesartan medoxomil placebo tablets
Sponsored by
Lee's Pharmaceutical Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 18-70 years of age (including 18 and 70 years of age), male or female;
  2. diagnosed with mild to moderate essential hypertension;
  3. clinic diastolic and systolic blood pressure need to meet the following two conditions: 3 times mean sitting diastolic blood pressure measurements at 95mmHg-110mmHg (not including 110mmHg); 3 times sitting systolic blood pressure measured and mean value between150mmHg-180mmHg (not including 180mmHg);
  4. understand clearly that voluntary to participate in the study, sign informed consent.

Exclusion Criteria:

  1. severe essential hypertension (sitting systolic ≥180mmHg and / or sitting diastolic pressure ≥110mmHg), malignant hypertension, hypertensive emergency, hypertensive crisis and high blood pressure encephalopathy.
  2. secondary hypertension.
  3. The following hypertension and diseases: acute myocardial infarction within 6 months, the cerebral artery accident, transient ischemic attack; or dissecting aortic aneurysm, angina, II-IVClass (NYHA classification) history of heart failure Ⅱ degree atrioventricular block, sick sinus integrated disease, bradycardia (heart rate <50 beats / min) or other antiarrhythmic drugs needed.
  4. significant laboratory abnormalities include: serum potassium> 5.5mmol / L; blood ALT or AST> 2.5ULN; serum creatinine> 1.5ULN.
  5. unilateral or bilateral renal artery stenosis.
  6. Type 1 diabetes and poor glycemic control of type 2 diabetes (HbA1c values ≥ 8%).
  7. gastrointestinal lesions or gastrointestinal surgery may affect drug absorption or excretion, such as stomach-bowel resection, nearly one year activity of gastrointestinal inflammation, ulcers or gastrointestinal bleeding.
  8. azilsartan sheet or olmesartan medoxomil tablets and related drugs (ARB, ACEI And renin inhibitors) allergies.
  9. pregnant, lactating female patients, or during the test does not guarantee the effective collision pregnant person.
  10. Obesity, body mass index (BMI)> 30kg / m2.
  11. Import of use in addition to import other types of medication trials of antihypertensive drugs, Anti-angina drugs, lithium agents, corticosteroids, licorice, estrogen, digitalis Drugs and drugs were potassium.
  12. Variance of diastolic blood pressure ≥8mmHg.
  13. drug or alcohol abuse within 6 months Are drinking more than two units of alcohol (1 unit = 360mL or 45mL alcohol content of 40%).

14 patients with malignant tumors. 15. hemodialysis patients or strictly limit salt therapy. 16. Participated in other clinical trials within 30 days.

Sites / Locations

  • Peking University First hospiatl

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment-Azilsartan

Positive Control-olmesartan medoxomil

Arm Description

Azilsartan tabelts

olmesartan medoxomil tablets

Outcomes

Primary Outcome Measures

Decrease of sitting diastolic blood pressure at week 16

Secondary Outcome Measures

Decrease of sitting diastolic blood pressure at week 8
Decrease of sitting systolic blood pressure at week 8
Decrease of sitting diastolic blood pressure at week 2
Decrease of sitting diastolic blood pressure at week 4
Decrease of sitting diastolic blood pressure at week 12
Decrease of sitting systolic blood pressure at week 2
Decrease of sitting systolic blood pressure at week 4
Decrease of sitting systolic blood pressure at week 12
decrease of 24-hour ambulatory blood pressure monitoring at week 16
do a 24-hour ambulatory blood pressure monitoring at baseline and at week 16, compare the decrease.

Full Information

First Posted
November 17, 2015
Last Updated
August 30, 2018
Sponsor
Lee's Pharmaceutical Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT02609490
Brief Title
Azilsartan in Chinese Patients With Mild and Moderate Hypertension
Official Title
A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
September 2015 (Actual)
Primary Completion Date
February 2017 (Actual)
Study Completion Date
August 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lee's Pharmaceutical Limited

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A phase 3 clinical study to evaluate the safety and efficacy of Azilsartan in Chinese hypertension patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
304 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment-Azilsartan
Arm Type
Experimental
Arm Description
Azilsartan tabelts
Arm Title
Positive Control-olmesartan medoxomil
Arm Type
Active Comparator
Arm Description
olmesartan medoxomil tablets
Intervention Type
Drug
Intervention Name(s)
Azilsartan tablets
Intervention Description
20mg/tablet
Intervention Type
Drug
Intervention Name(s)
Azilsartan placebo tablets
Intervention Description
placebo tablet
Intervention Type
Drug
Intervention Name(s)
Olmesartan medoxomil tablets
Intervention Description
20mg/tablet
Intervention Type
Drug
Intervention Name(s)
olmesartan medoxomil placebo tablets
Intervention Description
placebo tablet
Primary Outcome Measure Information:
Title
Decrease of sitting diastolic blood pressure at week 16
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Decrease of sitting diastolic blood pressure at week 8
Time Frame
8 weeks
Title
Decrease of sitting systolic blood pressure at week 8
Time Frame
8 weeks
Title
Decrease of sitting diastolic blood pressure at week 2
Time Frame
2 weeks
Title
Decrease of sitting diastolic blood pressure at week 4
Time Frame
4 weeks
Title
Decrease of sitting diastolic blood pressure at week 12
Time Frame
12weeks
Title
Decrease of sitting systolic blood pressure at week 2
Time Frame
2 weeks
Title
Decrease of sitting systolic blood pressure at week 4
Time Frame
4 weeks
Title
Decrease of sitting systolic blood pressure at week 12
Time Frame
12 weeks
Title
decrease of 24-hour ambulatory blood pressure monitoring at week 16
Description
do a 24-hour ambulatory blood pressure monitoring at baseline and at week 16, compare the decrease.
Time Frame
16 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-70 years of age (including 18 and 70 years of age), male or female; diagnosed with mild to moderate essential hypertension; clinic diastolic and systolic blood pressure need to meet the following two conditions: 3 times mean sitting diastolic blood pressure measurements at 95mmHg-110mmHg (not including 110mmHg); 3 times sitting systolic blood pressure measured and mean value between150mmHg-180mmHg (not including 180mmHg); understand clearly that voluntary to participate in the study, sign informed consent. Exclusion Criteria: severe essential hypertension (sitting systolic ≥180mmHg and / or sitting diastolic pressure ≥110mmHg), malignant hypertension, hypertensive emergency, hypertensive crisis and high blood pressure encephalopathy. secondary hypertension. The following hypertension and diseases: acute myocardial infarction within 6 months, the cerebral artery accident, transient ischemic attack; or dissecting aortic aneurysm, angina, II-IVClass (NYHA classification) history of heart failure Ⅱ degree atrioventricular block, sick sinus integrated disease, bradycardia (heart rate <50 beats / min) or other antiarrhythmic drugs needed. significant laboratory abnormalities include: serum potassium> 5.5mmol / L; blood ALT or AST> 2.5ULN; serum creatinine> 1.5ULN. unilateral or bilateral renal artery stenosis. Type 1 diabetes and poor glycemic control of type 2 diabetes (HbA1c values ≥ 8%). gastrointestinal lesions or gastrointestinal surgery may affect drug absorption or excretion, such as stomach-bowel resection, nearly one year activity of gastrointestinal inflammation, ulcers or gastrointestinal bleeding. azilsartan sheet or olmesartan medoxomil tablets and related drugs (ARB, ACEI And renin inhibitors) allergies. pregnant, lactating female patients, or during the test does not guarantee the effective collision pregnant person. Obesity, body mass index (BMI)> 30kg / m2. Import of use in addition to import other types of medication trials of antihypertensive drugs, Anti-angina drugs, lithium agents, corticosteroids, licorice, estrogen, digitalis Drugs and drugs were potassium. Variance of diastolic blood pressure ≥8mmHg. drug or alcohol abuse within 6 months Are drinking more than two units of alcohol (1 unit = 360mL or 45mL alcohol content of 40%). 14 patients with malignant tumors. 15. hemodialysis patients or strictly limit salt therapy. 16. Participated in other clinical trials within 30 days.
Facility Information:
Facility Name
Peking University First hospiatl
City
Beijing
ZIP/Postal Code
100000
Country
China

12. IPD Sharing Statement

Learn more about this trial

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

We'll reach out to this number within 24 hrs